ARK Genomic Revolution ETF Target of Unusually High Options Trading (BATS:ARKG)

ARK Genomic Revolution ETF (BATS:ARKG) was the target of unusually large options trading on Monday. Traders acquired 27,609 call options on the stock. This is an increase of approximately 155% compared to the typical daily volume of 10,820 call options.

Institutional Investors Weigh In On ARK Genomic Revolution ETF

A number of institutional investors and hedge funds have recently made changes to their positions in ARKG. Ascentis Independent Advisors purchased a new position in ARK Genomic Revolution ETF in the 1st quarter worth approximately $26,000. PNC Financial Services Group Inc. raised its position in shares of ARK Genomic Revolution ETF by 53.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock valued at $29,000 after buying an additional 378 shares in the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of ARK Genomic Revolution ETF by 734.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock worth $31,000 after acquiring an additional 984 shares during the last quarter. Western Wealth Management LLC purchased a new position in ARK Genomic Revolution ETF in the first quarter worth $37,000. Finally, Strategic Wealth Investment Group LLC purchased a new position in ARK Genomic Revolution ETF in the second quarter worth $38,000.

ARK Genomic Revolution ETF Stock Performance

BATS:ARKG traded up $0.87 during trading hours on Monday, reaching $42.30. The stock had a trading volume of 4,272,883 shares, compared to its average volume of 2,946,578. The stock has a 50 day simple moving average of $32.38 and a 200 day simple moving average of $30.33. ARK Genomic Revolution ETF has a 12-month low of $22.73 and a 12-month high of $42.70.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.